EMA and FDA Establish Joint Principles for AI in Medicine
Hover over text to view sources
The Ten Core Principles
The principles established by the EMA and FDA include:. Human-Centric by Design: AI technologies should align with ethical and human-centric values. Risk-Based Approach: The development and use of AI must follow a risk-based approach, ensuring appropriate validation and oversight based on the context of use. Adherence to Standards: AI technologies should comply with relevant legal, ethical, technical, and regulatory standards, including Good Practices (GxP). Clear Context of Use: There must be a well-defined context for the use of AI technologies, detailing their role and scope. Multidisciplinary Expertise: The integration of multidisciplinary expertise is essential throughout the AI technology's lifecycle. Data Governance and Documentation: Detailed documentation of data provenance and processing steps is required to ensure traceability and compliance with GxP. Model Design and Development Practices: AI technologies should follow best practices in design and leverage fit-for-use data, focusing on interpretability and predictive performance. Risk-Based Performance Assessment: Evaluations must consider the complete system, including human-AI interactions, using appropriate metrics for the intended context. Life Cycle Management: Quality management systems should be implemented throughout the AI technology's lifecycle to address issues effectively. Clear, Essential Information: Information regarding the AI technology's context of use, performance, and limitations should be presented in plain language to ensure accessibility for users and patients.Implications for Drug Development
The implementation of these principles is expected to facilitate more efficient pathways for both traditional and biological medicines. By adhering to these standards, pharmaceutical companies can better prepare for future regulatory guidelines while contributing to a global innovation environment that prioritizes patient safety. Mark Arnold, a principal at Bioanalytical Solution Integration, noted that these principles are designed to enhance the use of AI in generating evidence across all phases of the drug product lifecycle, ultimately improving healthcare outcomes. European Commissioner for Health and Animal Welfare, Olivér Várhelyi, emphasized that these guiding principles represent a renewed EU-US cooperation in the field of novel medical technologies. He stated that this collaboration showcases how both regions can work together to maintain their leadership in global innovation while ensuring the highest levels of patient safety.Conclusion
The joint principles established by the EMA and FDA mark a crucial development in the integration of AI within the pharmaceutical industry. By providing a structured approach to the use of AI, these guidelines aim to enhance the safety, efficacy, and efficiency of drug development processes. As AI technologies continue to evolve, ongoing collaboration between regulatory bodies will be essential to adapt these principles and ensure they meet the needs of a rapidly changing landscape in medicine development.Related articles
EU and US Establish Joint AI Principles for Medicines Industry
The European Medicines Agency and the US Food and Drug Administration have launched ten joint principles for the use of AI in the medicines industry. This initiative aims to harmonize regulatory practices and enhance patient safety while fostering innovation in drug development.
NVIDIA and Natera Collaborate on AI for Precision Medicine
NVIDIA and Natera have announced a collaboration to enhance AI foundation models for precision medicine. This partnership aims to leverage Natera's extensive datasets and NVIDIA's computing power to improve diagnostics and personalized therapies.
OpenAI and Anthropic Target Health Care for AI Expansion
OpenAI and Anthropic are positioning themselves to leverage AI in the health care sector, aiming to integrate health data into existing platforms rather than creating new applications. This strategy capitalizes on their established user bases and the evolving health care infrastructure.
Insilico Medicine's IPO Fuels AI-Driven Drug Discovery Success
Insilico Medicine has made headlines by successfully launching its IPO in Hong Kong, raising approximately $293 million. The company has quickly advanced its AI-driven drug candidate, rentosertib, into phase 2 trials for idiopathic pulmonary fibrosis, showcasing the potential of AI in accelerating drug discovery.
'90s Video Games Like 'Mario Kart' Boost Children's Brain Health, Claims Counselor
Mental health counselor Veronica Lichtenstein argues that video games from the 1990s, such as 'Mario Kart,' positively impacted children's cognitive development and mental health. In contrast, modern games are designed to promote addiction and lack the critical thinking challenges that older games provided.